[
  {
    "drug_id": 1,
    "name": "Osimertinib",
    "target_gene": "EGFR",
    "mutation_types": "T790M",
    "cancer_type": "Lung",
    "mechanism": "EFGR inhibitor",
    "ic50": 0.15,
    "confidence": 94,
    "side_effects": "rash, diarrhea, dry skin",
    "clinical_trial": "FLAURA Phase III",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 2,
    "name": "Olaparib",
    "target_gene": "BRCA1/2",
    "mutation_types": NaN,
    "cancer_type": "Breast, Pancreatic",
    "mechanism": "PARP inhibitor",
    "ic50": 0.22,
    "confidence": 91,
    "side_effects": "fatigue, anemia",
    "clinical_trial": "OlympiAD Trial",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 3,
    "name": "Crizotinib",
    "target_gene": "ALK",
    "mutation_types": "ALK fusion",
    "cancer_type": "Lung",
    "mechanism": "ALK inhibitor",
    "ic50": 0.3,
    "confidence": 89,
    "side_effects": "nausea, visual disturbances",
    "clinical_trial": "PROFILE 1014",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 4,
    "name": "Trastuzumab",
    "target_gene": "HER2",
    "mutation_types": "Amplification",
    "cancer_type": "Breast",
    "mechanism": "HER2 monoclonal antibody",
    "ic50": 0.12,
    "confidence": 95,
    "side_effects": "cardiotoxicity",
    "clinical_trial": "EMILIA",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 5,
    "name": "Dabrafenib",
    "target_gene": "BRAF",
    "mutation_types": "V600E",
    "cancer_type": "Melanoma",
    "mechanism": "BRAF inhibitor",
    "ic50": 0.25,
    "confidence": 90,
    "side_effects": "hyperkeratosis, fever",
    "clinical_trial": "BREAK-3",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 6,
    "name": "Vemurafenib",
    "target_gene": "BRAF",
    "mutation_types": "V600E",
    "cancer_type": "Melanoma",
    "mechanism": "BRAF inhibitor",
    "ic50": 0.33,
    "confidence": 88,
    "side_effects": "arthralgia, rash",
    "clinical_trial": "BRIM-3",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 7,
    "name": "Nivolumab",
    "target_gene": "PD-1",
    "mutation_types": "Overexpression",
    "cancer_type": "Multiple",
    "mechanism": "Immune checkpoint inhibitor",
    "ic50": 1.2,
    "confidence": 93,
    "side_effects": "fatigue, colitis",
    "clinical_trial": "CHECKMATE-067",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 8,
    "name": "Pembrolizumab",
    "target_gene": "PD-1",
    "mutation_types": "Overexpression",
    "cancer_type": "Multiple",
    "mechanism": "Immune checkpoint inhibitor",
    "ic50": 1.1,
    "confidence": 92,
    "side_effects": "fever, rash, hypothyroidism",
    "clinical_trial": "KEYNOTE-001",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 9,
    "name": "Atezolizumab",
    "target_gene": "PD-L1",
    "mutation_types": "Overexpression",
    "cancer_type": "Lung, Bladder",
    "mechanism": "PD-L1 inhibitor",
    "ic50": 0.98,
    "confidence": 90,
    "side_effects": "fatigue, decreased appetite",
    "clinical_trial": "IMpower110",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 10,
    "name": "Enzalutamide",
    "target_gene": "AR",
    "mutation_types": "Overexpression",
    "cancer_type": "Prostate",
    "mechanism": "Androgen receptor antagonist",
    "ic50": 0.21,
    "confidence": 87,
    "side_effects": "headache, hot flashes",
    "clinical_trial": "PREVAIL",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 11,
    "name": "Lapatinib",
    "target_gene": "HER2",
    "mutation_types": "Amplification",
    "cancer_type": "Breast",
    "mechanism": "Dual EGFR/HER2 inhibitor",
    "ic50": 0.45,
    "confidence": 86,
    "side_effects": "rash, diarrhea",
    "clinical_trial": "EGF100151",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 12,
    "name": "Sorafenib",
    "target_gene": "VEGFR",
    "mutation_types": NaN,
    "cancer_type": "Kidney, Liver",
    "mechanism": "Multi-kinase inhibitor",
    "ic50": 0.6,
    "confidence": 84,
    "side_effects": "hand-foot syndrome, hypertension",
    "clinical_trial": "SHARP",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 13,
    "name": "Erlotinib",
    "target_gene": "EGFR",
    "mutation_types": "L858r",
    "cancer_type": "Lung",
    "mechanism": "EFGR inhibitor",
    "ic50": 0.08,
    "confidence": 95,
    "side_effects": "rash, diarrhea",
    "clinical_trial": "BR.21",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 14,
    "name": "Axitinib",
    "target_gene": "VEGFR",
    "mutation_types": NaN,
    "cancer_type": "Kidney",
    "mechanism": "VEGFR inhibitor",
    "ic50": 0.19,
    "confidence": 85,
    "side_effects": "hypertension, fatigue",
    "clinical_trial": "AXIS",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 15,
    "name": "Everolimus",
    "target_gene": "Mtor",
    "mutation_types": NaN,
    "cancer_type": "Kidney, Breast",
    "mechanism": "Mtor INHIBITOR",
    "ic50": 0.55,
    "confidence": 83,
    "side_effects": "infections, stomatitis",
    "clinical_trial": "RECORD-1",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 16,
    "name": "Ibrutinib",
    "target_gene": "BTK",
    "mutation_types": "BTK mutation",
    "cancer_type": "Leukemia",
    "mechanism": "BTK inhibitor",
    "ic50": 0.11,
    "confidence": 91,
    "side_effects": "bleeding, infections",
    "clinical_trial": "RESONATE",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 17,
    "name": "Idelalisib",
    "target_gene": "PI3K?",
    "mutation_types": NaN,
    "cancer_type": "Lymphoma",
    "mechanism": "PI3K delta inhibitor",
    "ic50": 0.2,
    "confidence": 88,
    "side_effects": "diarrhea, hepatotoxicity",
    "clinical_trial": "ZETA",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 18,
    "name": "Venetoclax",
    "target_gene": "BCL-2",
    "mutation_types": "Overexpression",
    "cancer_type": "Leukemia",
    "mechanism": "BCL-2 inhibitor",
    "ic50": 0.13,
    "confidence": 92,
    "side_effects": "neutropenia, nausea",
    "clinical_trial": "M14-032",
    "approval_status": "FDA-approved"
  },
  {
    "drug_id": 19,
    "name": "Cabozantinib",
    "target_gene": "MET",
    "mutation_types": "MET exon 14 skip",
    "cancer_type": "Thyroid, Kidney",
    "mechanism": "Multi-kinase inhibitor",
    "ic50": 0.27,
    "confidence": 89,
    "side_effects": "diarrhea, fatigue",
    "clinical_trial": "EXAM",
    "approval_status": "FDA-approved"
  }
]